Voretigene Neparvovec for the Treatment of RPE65-associated Retinal Dystrophy: Consensus and Recommendations from the Korea RPE65-IRD Consensus Paper Committee
Korean Journal of Ophthalmology · 05.04.2023 · 37 (2) · 166-186
DOI: 10.3341/kjo.2023.0008 ↗Kurz gefasst
Fachartikel in der Zeitschrift Korean Journal of Ophthalmology, erschienen am 05.04.2023. Verfasst von Jinu Han und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Vision Research, Department of Ophthalmology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Retinal Dystrophies, Retinitis Pigmentosa. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 154 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Mutations in the RPE65 gene, associated with Leber congenital amaurosis, early-onset severe retinal dystrophy, and retinitis pigmentosa, gained growing attention since gene therapy for patients with RPE65-associated retinal dystrophy is available in clinical practice. RPE65 gene accounts for a very small proportion of patients with inherited retinal degeneration, especially Asian patients. Because RPE65-associated retinal dystrophy shares common clinical characteristics, such as early-onset severe nyctalopia, nystagmus, low vision, and progressive visual field constriction, with retinitis pigmentosa by other genetic mutations, appropriate genetic testing is essential to make a correct diagnosis. Also, fundus abnormalities can be minimal in early childhood, and the phenotype is highly variable depending on the type of mutations in RPE65-associated retinal dystrophy, which makes a diagnostic difficulty. The aim of this paper is to review the epidemiology of RPE65-associated retinal dystrophy, mutation spectrum, genetic diagnosis, clinical characteristics, and voretigene neparvovec, a gene therapy product for the treatment of RPE65-related retinal dystrophy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute of Vision Research, Department of Ophthalmology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
- Department of Ophthalmology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.
- Department of Ophthalmology, Chung-Ang University Gwangmyeong Hospital, Gwangmyeong, Korea.
- Department of Ophthalmology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.
- Department of Ophthalmology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
- Department of Ophthalmology, Soonchunhyang University Bucheon Hospital, Bucheon, Korea.
Zitieren
APA
Han, J., Joo, K., Kim, U. S., Woo, S. J., Lee, E. K., Lee, J. Y., Park, T. K., Kim, S. J., & Byeon, S. H. (2023). Voretigene Neparvovec for the Treatment of RPE65-associated Retinal Dystrophy: Consensus and Recommendations from the Korea RPE65-IRD Consensus Paper Committee. Korean Journal of Ophthalmology, 37(2), 166-186. https://doi.org/10.3341/kjo.2023.0008
Vancouver
Han J, Joo K, Kim US, Woo SJ, Lee EK, Lee JY, et al. Voretigene Neparvovec for the Treatment of RPE65-associated Retinal Dystrophy: Consensus and Recommendations from the Korea RPE65-IRD Consensus Paper Committee. Korean Journal of Ophthalmology. 2023;37(2):166-186. doi:10.3341/kjo.2023.0008
BibTeX
@article{Han2023,
author = {Han, Jinu and Joo, Kwangsic and Kim, Ungsoo Samuel and Woo, Se Joon and Lee, Eun Kyoung and Lee, Joo Yong and Park, Tae Kwann and Kim, Sang Jin and Byeon, Suk Ho},
title = {Voretigene Neparvovec for the Treatment of RPE65-associated Retinal Dystrophy: Consensus and Recommendations from the Korea RPE65-IRD Consensus Paper Committee},
journal = {Korean Journal of Ophthalmology},
year = {2023},
volume = {37},
number = {2},
pages = {166--186},
doi = {10.3341/kjo.2023.0008}
}
EUVIMED